Fatty liver disease is associated with obesity and type 2 diabetes, and hepatic lipid accumulation may contribute to insulin resistance. Histone deacetylase 3 (Hdac3) controls the circadian rhythm of hepatic lipogenesis. Here we show that, despite severe hepatosteatosis, mice with liver-specific depletion of Hdac3 have higher insulin sensitivity without any changes in insulin signaling or body weight compared to wild-type mice. Hdac3 depletion reroutes metabolic precursors towards lipid synthesis and storage within lipid droplets and away from hepatic glucose production. Perilipin 2, which coats lipid droplets, is markedly induced upon Hdac3 depletion and contributes to the development of both steatosis and improved tolerance to glucose. These findings suggest that the sequestration of hepatic lipids in perilipin 2-coated droplets ameliorates insulin resistance and establish Hdac3 as a pivotal epigenomic modifier that integrates signals from the circadian clock in the regulation of hepatic intermediary metabolism. npg
Hepatosteatosis, the defining clinical hallmark of nonalcoholic fatty liver disease (NAFLD), is one of the most prevalent metabolic disor ders throughout the world 1, 2 . NAFLD has been shown to be highly correlated with insulin resistance in many epidemiological studies, leading to speculation of a cause and effect relationship between the two 3, 4 . Insulin resistance in muscle and adipose tissue may increase the influx of carbohydrates and free fatty acids (FFAs) into the liver and thus promote hepatic de novo lipogenesis and triglyceride synthe sis. Hyperinsulinemia, resulting from a compensation by the pancreas for systemic insulin resistance, also reinforces hepatic lipogenesis and therefore contributes additionally to the development of hepatostea tosis 2, 5 . In addition, intrahepatic accumulation of triglycerides may generate various deleterious lipid intermediates, including diacyl glycerols (DAG) and ceramide, which could activate several cytosolic protein kinases either directly or indirectly through inflammation, resulting in the modification and disruption of insulin signaling and causing lipotoxicity and insulin resistance 4, 6 .
These theories can have a major impact on the treatment of both NAFLD and diabetes. However, the use of insulin sensitizers to treat NAFLD in clinical trials has generated mixed outcomes 3, 7 . Indeed, recent research has revealed that the interrelationship between hepato steatosis and hepatic insulin resistance is complex 1, 8 . For example, the role of insulin resistance in the pathogenesis of NAFLD is supported by the observation that in humans most hepatic lipid is derived from adiposesecreted FFAs and de novo lipogenesis rather than directly from the diet 9 and that insulin resistance precedes hepatosteatosis in several animal models of overnutritioninduced NAFLD 10 . And yet even in the face of this insulin resistance, intact insulin signal ing through insulin receptors, phosphoinositide3 kinases and Akt (also known as protein kinase B) is required to drive lipogenesis and hepatosteatosis, as has been shown using several knockout mouse models [11] [12] [13] [14] . In addition, hepatic insulin hypersensitivity in the phos phatase and tensin homolog (Pten) liverspecific knockout mouse is sufficient to cause hepatosteatosis 15 . As for the role of hepatosteatosis in insulin resistance, DAG and other lipid intermediates have been shown to activate protein kinase Cε (Prkce) and other cytosolic stress signals or inflammation, leading to the disruption of insulin signal ing 6 . However, elevated total hepatic content of these lipid intermedi ates does not always cause hepatic insulin resistance, suggesting that the detailed composition of hepatic lipid species, as well as their spatial distribution, may matter in this process 1, 8, [16] [17] [18] .
Although genetic factors contribute to the development of meta bolic syndromes, environmental factors including diet, exercise and rotating work shifts are also key determinants 19, 20 . The environment regulates the expression of genes involved in carbohydrate and lipid metabolism by altering the epigenome, including changes in the histone acetylation patterns in chromatin 21 that follow circadian rhythms 22, 23 . Histone acetylation is governed by opposing functions of two classes of enzymes: histone acetyltransferases and histone deacetylases (HDACs). Given the availability of many small molecules that activate or inhibit HDAC activities and the therapeutic potential of these small molecules in treating a variety of diseases, including metabolic disorders 24 , it is of great interest and importance to under stand the biology of individual HDACs in metabolic regulation.
We recently showed that Hdac3 colocalizes with nuclear receptor co repressor (Ncor1) in chromatin near genes involved in lipid metabolism in mouse liver in a circadian pattern, with the maximum occupancy occurring during the day and the minimum occurring at night 22 . This rhythm is orchestrated by nuclear receptor subfamily 1, group D, member 1 (Nr1d1), a nuclear receptor and key component of the molec ular circadian clock machinery 22, 25 . These findings, along with those of others, show that Hdac3 is crucial for the maintenance of hepatic lipid homeostasis 22, 25, 26 . However, it is unknown how hepatic Hdac3 regulates carbohydrate metabolism. Here we show that the severe hepa tosteatosis caused by loss of Hdac3 in mouse liver engenders a notably insulinhypersensitive state. Systematic characterization of the physi ological function of hepatic Hdac3 in energy metabolism establishes Hdac3 as a pivotal regulator of hepatic glucose production through a previously unsuspected mechanism involving the rerouting of metabo lites between lipid synthesis and glucose production pathways.
RESULTS

Hdac3 depletion is distinct from diet-induced hepatosteatosis
To delete Hdac3 specifically in the liver, we injected adult Hdac3 flox/flox C57BL/6 mice 27 with adenoassociated virus (AAV) expressing either Cre recombinase or control GFP driven by the thyroxinebinding globulin (Tbg) promoter (AAVTbgCre or AAVTbgGFP, respec tively), which specifically targets hepatocytes and not Kupffer cells or endothelial cells 28 . We confirmed the hepatocytespecific expression by immunohistochemistry of the livers from mice injected with AAVTbg GFP (Supplementary Fig. 1a ). Also by injecting mature mice, a direct assessment of hepatic Hdac3 function in the adult organ was achieved without any potential interference with proper embryonic or neonatal development that might alter adult hepatic function. This acute dele tion approach also makes it possible to distinguish the direct effects of Hdac3 deletion from any secondary or compensatory effects. Depletion of hepatic Hdac3 was complete by 1 week after injection with AAVTbg Cre compared to the AAVTbgGFP control injection (Fig. 1a) . Hepatic triglyceride content was significantly elevated twofold to threefold at 1 week after injection and was further increased fivefold to tenfold fold by 2-3 weeks after injection in the AAVTbgCre mice compared to the control AAVTbgGFP mice (Fig. 1b) . In contrast, mice with Hdac3 depleted in their macrophages using lysozyme MCre (LysM Cre; Hdac3 flox/flox mice) 27 did not develop fatty livers ( Supplementary  Fig. 1b ). Accumulation of very small lipid droplets within the hepato cytes of AAVTbgCre mice was evident after H&E staining ( Fig. 1c) . Exogenous Flagtagged Hdac3 protein, when introduced using AAV (AAVHdac3) at amounts similar to those of endogenous Hdac3 (Fig. 1d) , was able to completely rescue hepatosteatosis, as assessed by triglyceride measurement and Oil Red O staining ( Fig. 1e,f) . These results show that the metabolic phenotype of the AAVTbgCre-injected mice was indeed a result of the lack of Hdac3 in hepatocytes. To determine whether Hdac3 has a role in highfat diet (HFD) induced hepatosteatosis 10 , we superimposed depletion (by AAVTbg Cre) and overexpression of Hdac3 (by AAVHdac3) in mouse liver on a HFD feeding regimen. HFD feeding for 8 weeks did not alter the amounts of endogenous or overexpressed exogenous Hdac3 ( Fig. 1g) and had a synergistic effect with Hdac3 depletion in terms of promot ing hepatosteatosis (Fig. 1h) . In addition, Hdac3 overexpression did not ameliorate HFDinduced hepatosteatosis ( Fig. 1h ), suggesting that HFD feeding and hepatic Hdac3 depletion probably result in hepato steatosis through independent mechanisms. Consistent with this, the morphologic changes in the liver differed drastically in HDF feeding compared to Hdac3 depletion. Whereas Hdac3 depletion caused the formation of tiny lipid droplets that were barely discernable under low magnification, HFD feeding resulted in the accumulation of much bigger lipid droplets that were primarily restricted to the central vein areas (Fig. 1i) . Depletion of Hdac3 in the setting of the HFD led to a striking reduction in the size of the lipid droplets (comparing mice injected with AAVTbgCre on the HFD to mice injected with AAV TbgGFP on the HFD), even though the total lipid content was higher in the AAVTbgCre HFD group than the AAVTbgGFP HFD group (Fig. 1h,i) . Therefore, liverspecific depletion of Hdac3 in adult mice causes hepatosteatosis that is distinct from that caused by a HFD.
Glucose output and insulin sensitivity in the Hdac3-null liver
Despite the marked accumulation of triglycerides in the liver, mice lacking hepatic Hdac3 (AAVTbgCre mice) had lower fasting blood glucose concentrations at 2 weeks after injection compared to the AAV TbgGFP control mice ( Fig. 2a ). This suggests that Hdac3 normally promotes hepatic glucose production dur ing fasting. Mice without hepatic Hdac3 also had lower basal blood insulin concentrations ( Fig. 2b) and were more tolerant to glucose and insulin than the AAVTbg control mice ( Fig. 2c,d ), suggesting insulin hypersensitivity in these mice. Although most of the studies were performed in males, we observed similar phenotypes in female mice ( Supplementary  Fig. 2a,b) . These results are in line with a previous study reporting that mice with in utero depletion of hepatic Hdac3 using albuminCre (AlbCre; Hdac3 flox/flox mice) develop hypoglycemia and hypoinsulin ema, although that study was confounded by bodyweight differ ences between genotypes and did not detect significant differences for wholebody glucose tolerance 26 . Here, depletion of hepatic Hdac3 in adult mice did not alter body weight at up to 4 weeks after injection of AAVTbgCre compared to injection of AAVTbgGFP or compared to noninjected controls ( Fig. 2e and data not shown).
The greater glucose tolerance in AAVTbgCre mice compared to AAVTbgGFP mice was even more prominent when the mice were exposed to HFD ( Fig. 2f) , again without any accompanying differences in bodyweight gain ( Supplementary Fig. 2c ) despite the severe hepatosteatosis in the livers of the Hdac3depleted mice ( Supplementary Fig. 2d ). Hyperinsulinemiceuglycemic clamp studies using 3 Hglucose as a tracer revealed that insulinmediated suppression of hepatic glucose production was significantly potenti ated in the absence of hepatic Hdac3 compared to AAVTbgGFP controls, resulting in a higher glucose infusion rate in the clamp state in the Hdac3depleted mice ( Fig. 2g and Supplementary Fig. 2e,f) . The apparent lack of difference in basal hepatic glucose production in AAVTbgGFP and AAVTbgCre mice is probably the result of the lower basal blood insulin concentrations in mice without hepatic Hdac3 compared to the AAVTbgGFP control mice. Thus, the loss of hepatic Hdac3 results in insulin hypersensitivity and lower hepatic glucose production despite greater hepatic lipid accumulation. npg
The prominent dissociation of hepatic steatosis from insulin resist ance in Hdac3depleted livers prompted us to further examine the insulin signaling pathway. We found that insulindependent phos phorylation of Akt was not altered as a result of Hdac3 depletion in either the livers or isolated primary hepatocytes of mice in response to different dosages of insulin ( Fig. 3a,b and Supplementary Fig. 3a,b) . Macrophage infiltration and expression of proinflammatory genes also remained unaltered in the Hdac3depleted mice ( Supplementary  Fig. 3c,d) . Total hepatic ceramide content was also not changed in these mice ( Fig. 3c) , although several ceramide species showed modest increases in concentration ( Supplementary Fig. 3e ). Hepatic DAG concentrations were indeed prominently elevated in AAVTbgCre mice ( Fig. 3d and Supplementary Fig. 3f ) but did not lead to Prkce activation ( Fig. 3e) , whereas HFDinduced hepatosteatosis did ( Supplementary Fig. 3g ). These results suggest that accumulated lipid species were somehow sequestered from activating cytosolic kinases such as Prkce and were restrained from inducing inflamma tory responses, which may underlie the dissociation of hepatosteatosis from insulin resistance 29 .
Hdac3 controls metabolic rerouting and lipid sequestration From a metabolic kinetic perspective, hepatosteatosis is a result of an imbalance of hepatic triglyceride secretion, de novo lipogenesis, fatty acid oxidation and fatty acid uptake 5 . The hepatic triglyceride secretion rate, determined in vivo by measuring plasma triglyceride concentrations in a time course after blocking its turnover with the detergent Pluronic 407, was not affected by Hdac3 depletion (Fig. 4a) . The hepatic de novo lipogenesis rate, measured in vivo by tracing newly synthesized oleate from deuterated water, was higher in Hdac3 depleted livers compared to livers from AAVTbgGFP controls ( Fig. 4b) . Fatty acid oxidation and uptake were evaluated together in primary hepatocytes isolated from both groups of mice by measuring the production of 3 Hlabeled water from 3 Hpalmitate and the acqui sition of 3 Hpalmitate into the intracellular lipid pool, respectively. Hdac3depleted hepatocytes showed a lower fatty acid oxidation rate compared to hepatocytes from the AAVTbgGFP controls ( Fig. 4c) . Compared to the AAVTbgGFP controls, we found more 3 Hpalmitate in the intracellular lipid pool in the absence of Hdac3, with the net gain in fatty acid acquisition being roughly equal to the loss in fatty acid oxidation ( Fig. 4d) . Considering the unaltered triglyceride secre tion in Hdac3depleted mice, this suggests that the fatty acid uptake process per se was minimally affected by Hdac3 depletion.
In keeping with the metabolic tracing studies, a comprehensive gene expression analysis showed that Hdac3 deletion in the liver caused the prominent upregulation of genes that promote lipid sequestration, lipid synthesis and NADPH synthesis ( Fig. 4e and Gene Expression Omnibus GSE25937). Upregulated expression of Me1 (malic enzyme 1) and Cs (citrate synthase) suggests an enhanced pyruvatemalate cycle that supplies NADPH and acetylCoA for lipid synthesis (Fig. 4e,f) . Upregulated Pygl (glycogen phosphorylase) and G6pdx and G6pd2 (glucose6phosphate dehydrogenase), along with downregulated Pfkfb3 (6phosphofructo2kinase) 30, 31 , predict that glycogen would be consumed to feed into the pentose phosphate pathway, providing NADPH for lipid synthesis (Fig. 4e,f) . Indeed, the hepatic glycogen content was significantly lower in the Hdac3 depleted livers compared to livers from the AAVTbgGFP controls ( Fig. 4g and Supplementary Fig. 4a ). Mice without hepatic Hdac3 also had modestly higher FFA concentrations in their serum com pared to the AAVTbgGFP control mice ( Supplementary Fig. 4b ), potentially because of enhanced fat mobilization in adipose tissues as a result of lower blood insulin concentrations.
The expression of Srebp (sterol regulatory elementbinding pro teins) was not altered by Hdac3 depletion (Supplementary Fig. 4c ). This, together with the finding that the genomewide binding of Srebp proteins does not extensively overlap with the binding of Hdac3 in mouse liver 22, 32, 33 , suggests that Srebp proteins probably did not contribute substantially to the hepatosteatosis phenotype in the Hdac3depleted liver. Expression of other transcriptional regulators of lipogenesis, including Lxr (liver X receptors, also known as Nr1h) and Mlxipl (carbohydrate response elementbinding protein), was unchanged as a result of Hdac3 depletion (Supplementary Fig. 4c) , which is consistent with the conclusion that Hdac3 directly represses the transcription of the lipogenic genes to which it is recruited by Nr1d1 (ref. 22) . The expression of genes involved in fatty acid oxida tion (FAO) was unchanged or even upregulated by Hdac3 depletion (Supplementary Fig. 4d ), despite lower FAO flux ( Fig. 4c ) and fast ing serum ketone concentrations in Hdac3depleted mice compared to AAVTbgGFP controls (Fig. 4h) . These observations, along with the lack of accumulation of acylCoA in the liver (Fig. 4i) or acylcar nitines in the plasma (Supplementary Fig. 4e ) of Hdac3depleted mice, suggest that the FAO pathway is not inherently defective but, rather, is dominated by the enhanced lipid synthesis pathway in the Hdac3depleted liver. This domination could be accomplished through inhibition of the transport of acylCoA into mitochondria by glycerol3phosphate acyltransferase 1 (Gpam) and acetylCoA carboxylase 2 (Acacb) 5, 34 (Fig. 4f) .
The finding that the concentrations of acylCoA species were lower in Hdac3depleted livers compared to AAVTbgGFP control npg livers despite the accumulation of triglycerides ( Fig. 4i ) suggests that these intermediates were shunted toward glycerolipid formation and the subsequent sequestration in lipid droplets in the Hdac3depleted livers. Indeed, Plin2 (perilipin 2), Cidec (celldeath-inducing DFFA like effector c), Fitm1 (fat storageinducing transmembrane protein 1) and G0S2 (G0/G1 switch gene 2), which encode proteins involved in lipolysis inhibition and lipid sequestration 16, [35] [36] [37] , were among the most prominently upregulated genes in the Hdac3depleted liver ( Fig. 4e) . Their protein products were similarly upregulated and were associated with lipid droplets (Supplementary Fig. 5a,b ) in a highly specific manner, as other proteins associated with lipid drop lets, such as Plin3, Cideb and Cidea, were not significantly changed in response to Hdac3 depletion (Supplementary Fig. 5b,c) . Thus, enhanced lipid sequestration causes a reduced availability of fatty acids to the FAO machinery in mitochondria, resulting in reduced FAO activity without an accumulation of acylCoA. In sharp contrast, HFDinduced fatty liver is associated with higher concentrations of hepatic acylCoA species [38] [39] [40] compared to chowfed controls. When compared to Hdac3 depletion at the same degree of hepato steatosis, HFD feeding caused less upregulated expression of the genes involved in lipid storage and sequestration ( Supplementary  Fig. 6a,b) , highlighting the key role of intracellular lipid sequestra tion in combating lipotoxicity. Together, these results suggest that loss of Hdac3 derepresses metabolic genes and reroutes metabolites toward lipid synthesis and intracellular sequestration, which under lies hepatosteatosis.
Metabolic rerouting reduces hepatic glucose production We next addressed the mechanism underlying the regulation of glu cose metabolism by Hdac3. In primary hepatocytes isolated from fasted mice without hepatic Hdac3, glucose production from the precursors lactate and pyruvate was significantly lower compared to that seen in primary hepatocytes from AAVTbgGFP control mice (Fig. 5a) . In addition, the already high concentrations of intracellular triglyceride in Hdac3depleted hepatocytes were further increased after exposure to lactate and pyruvate for 2 h (Fig. 5a ), suggesting that these gluconeogenic precursors were rerouted into intracellular lipid pools instead of being used for glucose production. Indeed, the reduction in glucose output calculated in the number of carbon atoms was nearly 3 µmol per mg protein during the 2 h period, and the increase in intracellular triglyceride was about 2 µmol carbon atoms per mg protein (based on the mass of tripalmitin). Considering that only two out of the three carbons in lactate and pyruvate contribute to lipogenesis, these data strongly support the hypothesis that the reduced gluconeogenesis in the absence of Hdac3 is explained by enhanced lipogenesis. npg Hdac3 was recently suggested to be directly involved in forkhead box O1 (Foxo1)mediated transcriptional control of hepatic gluco neogenesis 41 . However, we found that deletion of Hdac3 in the liver did not alter the expression of key gluconeogenic genes, including Ppargc1a (peroxisome proliferatoractivated receptor γ coactivator 1α), G6pc (glucose 6phosphatase) and Pck1 (phosphoenolpyruvate carboxykinase), under either fed or fasting conditions (Fig. 5b) . To address whether Hdac3 is required specifically for Foxo1mediated transcription, mice with or without hepatic Hdac3 were injected with adenovirus expressing constitutively active Foxo1. A gene expression analysis in the livers of these mice showed that the loss of Hdac3 did not interfere with Foxo1dependent transcription of its target genes Igfbp1 and Pck1 (Fig. 5c) . These data suggest that gluconeogenesis is not inherently defective in the Hdac3depleted liver.
To circumvent the competition for substrates from lipogenesis, we sought to determine whether the lower glucose production in Hdac3 depleted hepatocytes compared to AAVTbgGFP control hepatocytes could be rescued with substrates that are more direct precursors for gluconeogenesis but are less direct precursors for lipogenesis. Lactate and pyruvate were unable to rescue the lower glucose production even at high concentrations (Fig. 5d) , presumably because of the enhanced pyruvatemalate cycle that is driven by continuous consumption of acetylCoA and NADPH in lipogenesis ( Fig. 4f) and because of potentially limited pyruvate carboxylase activities resulting from low concentrations of acetylCoA ( Fig. 4i) . Glycerol significantly boosted glucose production in Hdac3depleted hepatocytes but could not com pletely rescue it (Fig. 5d) , which is in line with the fact that glycerol bypasses the citric acid cycle when it is used for gluconeogenesis but can also be directly used for fatty acid esterification. Fructose, a more direct glucose precursor, when used at a concentration (10-25 mM) well above its K m for hexokinase (about 1-2 mM), completely res cued glucose production in Hdac3depleted hepatocytes (Fig. 5d) , excluding the possibility of any inherent defects in the last several steps of gluconeogenesis, including the step catalyzed by G6pc, in these cells. Exposing hepatocytes to a fatty acid synthase inhibitor, C75, also masked the difference in glucose production between Hdac3depleted and control AAVTbgGFP hepatocytes (Fig. 5d) , supporting the notion that the metabolic rerouting toward lipid syn thesis and sequestration contributes to the lower glucose production in Hdac3depleted hepatocytes.
Lipid sequestration, steatosis and insulin resistance
Our studies in primary hepatocytes provided in vitro evidence that hepatic glucose production is dominated by the lipid synthesis and sequestration pathway when Hdac3 is depleted. To test this hypothesis in vivo, we sought to specifically inhibit lipid synthesis and sequestration in the liver. Several considerations prompted us to target Plin2: (i) the lipiddroplet-coating protein has been known to have an essential role in lipid sequestration and the inhibition of basal lipolysis 35 ; (ii) our gene expression analysis showed that Plin2 is among the most prominently upregulated genes in the Hdac3depleted liver; (iii) it is known that Plin2 is required for hepatosteatosis and for upregulated lipogenic gene expression under prodiabetic conditions 42, 43 ; and (iv) antisense oligonucleotides (ASO) against Plin2 are available for liverspecific knockdown 43 .
We found that treatment of AAVTbgCre and AAVTbgGFP con trol mice with ASO against Plin2 blunted the prominent upregulation of Plin2 by Hdac3 deletion in liver (Fig. 6a) . Consistent with previ ous findings 43 , knockdown of Plin2 suppressed the hepatic de novo lipogenesis flux that was enhanced by Hdac3 deletion (Fig. 6b) , sug gesting that crosstalk exists between lipid storage and lipid synthesis. Plin2 knockdown clearly ameliorated the hepatosteatosis induced by Hdac3 depletion (Fig. 6c,d) , and the steatotic areas that remained after Plin2 knockdown were primarily in regions that were proximal to central veins (Fig. 6c) . Thus, enhanced lipogenesis and lipid seques tration contributed substantially to the development of hepatosteato sis after Hdac3 depletion. Of note, although Plin2 knockdown did not alter body weight in either the Hdac3depleted or the AAVTbgGFP control mice (Fig. 6e) , it did blunt the improved tolerance to glu cose (Fig. 6f,g) and insulin (Fig. 6h,i) in the hepatic Hdac3depleted mice, strongly supporting the notion that lipid sequestration is a key causal factor in the dissociation of hepatosteatosis from insulin npg resistance. Consistent with this, hepatic overexpression of Plin2 ( Supplementary  Fig. 7a,b) in wildtype mice caused hepato steatosis (Supplementary Fig. 7c,d ) that was associated with hypoglycemia ( Supplementary Fig. 7e ), hypoin sulinemia (Supplementary Fig. 7f ) and improved wholebody insulin sensitivity (Supplementary Fig. 7g ) without any associated changes in body weight (Supplementary Fig. 7h ). Collectively, these data show that enhanced lipid synthesis and sequestration contribute to altered carbohydrate metabolism and insulin hypersensitivity in mice lacking hepatic Hdac3.
DISCUSSION
The liver is the central nexus of energy metabolism and governs the fate of substrates in response to nutritional and hormonal signals. Under normal physiological conditions, both hepatic glu cose production and lipid synthesis have a circadian rhythm 20 . Our findings establish that the rhythmic rerouting of metabolic inter mediates between the two synthetic pathways is directly regulated by the molecular circadian clock through the epigenomic modifier Hdac3 (Supplementary Fig. 8 ). During the day, when the nocturnal mouse is inactive and feeding less, Hdac3 is recruited to the genome and represses the expression of genes involved in lipid synthesis and sequestration, allowing for metabolic precursors to be directed toward gluconeogenesis to maintain normoglycemia. During the active and feeding night period, the virtual absence of Hdac3 at these genomic regions derepresses lipogenesis and reroutes metabolic inter mediates toward lipid synthesis for energy storage at the expense of glucose production. This model is supported by the following findings: (i) depletion of Hdac3 in the liver results in the upregulation of genes involved in lipid synthesis and sequestration but does not alter the expression of key gluconeogenic genes; (ii) the chromatin occupancy of Hdac3 is predominantly on genes involved in lipid metabolism and has a circadian pattern, with the maximum occupancy occurring during fasting and minimum occupancy occurring during feeding 22 ;
(iii) hepatic glycogen concentrations are reduced by Hdac3 deletion, contrary to what would be expected if there was a primary defect in G6pc activity and an inability to generate glucose from glycogen 41, 44 ;
(iv) glucose synthesis from the canonical precursors pyruvate and lactate is reduced in hepatocytes by Hdac3 depletion concurrently with an increase in lipid synthesis from the same precursors; (v) the low glucose production in Hdac3depleted hepatocytes can be rescued by fructose, a sixcarbon precursor of glucose, or by the inhibition of lipid synthesis, suggesting that gluconeogenesis is inherently intact but is dominated by the routing of threecarbon metabolites toward lipid synthesis; (vi) the low acetylCoA content is accompanied by an enhanced lipogenesis flux in the Hdac3depleted liver, suggesting that acetylCoA is shunted toward lipogenesis, which may limit the activity of pyruvate carboxylase and thus reduce gluconeogenesis; (vii) the improved glucose and insulin tolerance in Hdac3 liver specific knockout mice is attenuated by the suppression of the meta bolic rerouting toward lipid synthesis and storage through knockdown of the lipidsequestering and lipiddroplet-coating protein Plin2; and (viii) overexpression of Plin2 in the livers of wildtype mice results in hepatosteatosis and improved insulin sensitivity, mimicking the metabolic phenotype in mice without hepatic Hdac3
We here highlight the integrated nature of metabolism. Our results show that a given metabolic process can be modulated by the rerout ing of metabolites without altering the enzymes that are immediately involved in that process, as exemplified by the indirect regulation of gluconeogenesis by Hdac3. Notably, a parallel and independent meta bolic rerouting may be coordinated by hepatic Foxo proteins, which npg are active in driving gluconeogenic gene expression during fasting and are inhibited by Aktmediated phosphorylation and p300mediated acetylation during feeding 45 . Constitutively active Foxo1 increases glucose production and seems to reduce hepatic lipid output, as evi denced by hypolipidemia 46, 47 . Conversely, depletion of hepatic Foxo proteins decreases glucose production and tends to increase lipid syn thesis, as evidenced by hepatosteatosis or hyperlipidemia 48, 49 . In both situations, the effects of Foxo proteins on gluconeogenesis are through wellcharacterized direct transcriptional activation, whereas the effects of the Foxo proteins on lipid metabolism are less well defined and are still under debate. Of note, the acetylation of the Foxo proteins decreases their transactivation activity 45 , and it has been shown that recombinant Hdac3 protein can deacetylate Foxo1 in vitro 41 . However, our findings that depletion of Hdac3 in the liver does not alter Foxo1 dependent transcription and does not cause the predicted accumula tion of glycogen clearly indicate that the potential deacetylation of Foxo1 is not essential for the effects of Hdac3 on glucose metabolism in vivo. We speculate that Foxomediated transcriptional activation and Hdac3mediated transcriptional repression may function collec tively, but independently, to divert metabolic intermediates between glucose production and lipid synthesis during the fastingfeeding and lightdark cycles. Although Hdac3 clearly functions as an epigenomic modifier in the liver 22 , it may also have nonhistone protein targets, as well as deacetylaseindependent functions.
In contrast to the circadian shifting between hepatic lipogenesis and gluconeogenesis under normal physiological conditions, pathological overnutrition provides excess metabolic intermediates that oversaturate and constantly activate both pathways. This leads to the coexistence of hepatosteatosis and insulin resistance. However, the concurrent insulin hypersensitivity and severe hepatosteatosis present in mice without hepatic Hdac3 clearly shows that hepatosteatosis and insulin resistance per se do not necessarily have a cause and effect relationship. Among the most prominently upregulated genes in the Hdac3depleted liver are those encoding lipiddroplet-associated proteins, including Plin2, Cidec, Fitm1 and G0S2, which negatively regulate lipolysis and the subsequent release of lipids in a cooperative manner 8, 16, [35] [36] [37] 50, 51 . Low acylCoA content is accompanied by a reduced FAO flux in the Hdac3 depleted liver, suggesting that acylCoA is shunted toward glycerolipid synthesis and the subsequent sequestration from mitochondrial oxida tion machinery. Prkce activity and inflammation are not enhanced in the Hdac3depleted liver, despite elevated total DAG and triglyceride contents, suggesting that these lipids are sequestered in lipid droplets and, hence, prevented from activating cytosolic kinases. Dampening the upregulation of Plin2 masked the insulin hypersensitivity in mice without hepatic Hdac3, whereas hepatic overexpression of Plin2 in wildtype mice resulted in steatosis and improved wholebody insulin sensitivity, supporting an essential role of intracellular lipid seques tration in preventing lipotoxicity and lipidinduced hepatic insulin resistance. Consistent with our findings, the insulinsensitizing effect of Plin2 was observed previously in cultured hepatocytes in which depletion of Plin2 and other perilipin proteins decreased the cellu lar responses to insulin 52 . In addition, dissociation of hepatosteatosis from insulin resistance was observed in mice and humans that were deficient in either lipolysis or hepatic triglyceride secretion 8, 18, [53] [54] [55] . All these findings can be unified under the hypothesis that hepatic insulin resistance is determined by whether lipid droplets sequester lipid content well enough to prevent the cytosolic accumulation of deleterious lipid species.
Although hepatic lipogenesis is upregulated and required for the development of steatosis in both chowfed mice lacking hepatic Hdac3 and wildtype mice on a HFD, a key difference between these two groups is in the balance between the capacity for lipid sequestration and the content of metabolic intermediates. In overnutrition mouse models (HFD or ob/ob), excess delivery of metabolic intermediates to the liver is the primary event, whereas increased hepatic lipid synthe sis and storage is an adaptive response. However, the lipid sequestra tion capacity is insufficient relative to the overwhelming lipid content influx, leading to the accumulation of harmful lipid intermediates that promote insulin resistance. In this context, the ablation of Plin2 reduces lipid synthesis and thus reduces the generation of harmful lipid species, leading to improved insulin sensitivity 43, 56 . In the Hdac3 deficient mouse model, the primary event of upregulated lipogenesis diverts metabolic precursors away from glucose production. In addi tion, reduced fatty acid oxidation and acetylCoA concentrations may contribute to a decrease in pyruvate carboxylase activity and thus limit the flux of pyruvate to glucose production. Collectively, these changes result in reduced glucose output and insulin hypersensitivity. Knockdown of Plin2 on this background reduces lipid synthesis and metabolic rerouting and therefore ameliorates insulin hypersensitiv ity. This highlights the concept that hepatic lipid accumulation has a diverse pathogenesis and requires specifically targeted therapies, which is crucial to consider in light of the failure of large therapeutic trials (such as the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial) that lump all diabetes together 57 .
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Mice. We have previously described the C57BL/6 Hdac3 flox/flox mice 27 . We housed mice under a 12 h light and 12 h dark cycle (lights on at 7 a.m. and lights off at 7 p.m.). We used adult male mice at the age of 3-7 months in all experiments, except where otherwise indicated. The Penn Vector Core gener ated the AAV vectors (AAV2/8TbgGFP and AAV2/8TbgCre). We injected each AAV vector intravenously at 1.5 × 10 11 genome copies per mouse and characterized the mice at 1-3 weeks after AAVTbgCre injection. For the inves tigation of Foxo1 overexpression, we intravenously injected adenovirus vectors expressing GFP or Foxo1TSS at 1.3 × 10 9 infection units (IFU) per mouse. The adenovirus used for the overexpression of Plin2 was previously described 58 . For Plin2 knockdown, we intraperitoneally injected either control or Plin2 ASO at 25 mg per kg body weight twice per week for 4-5 weeks. We harvested tissues at 5 p.m. without restricting the mice to food or water, unless otherwise indicated. We performed glucose tolerance tests and insulin tolerance tests after fasting the mice for 6 h, beginning at 9 a.m. For the glucose tolerance test, we injected glucose intraperitoneally at 1.5 g or 2 g per kg body weight. For the insulin tolerance test, we intraperitoneally injected insulin (Novolin R) into the mice at 0.6 U per kg body weight. For the insulin signaling analysis, we fasted mice overnight, intraperitoneally injected them with insulin at 2 U or 0.5 U per kg body weight and harvested the tissue after 20 min. We measured blood glucose concentrations using a glucometer (OneTouch) by sampling from the tail. HFD containing 60 kcal % fat was purchased from Research Diets Inc. (D12492i). All the animal care and use procedures followed the guidelines of the Institutional Animal Care and Use Committee of the University of Pennsylvania in accord ance with the guidelines of the US National Institutes of Health.
Western blot, fractionation and gene expression analysis.
For the western blot of the total lysates, we lysed tissues or cells in radioimmunoprecipitation assay (RIPA) buffer supplemented with phosphatase and protease inhibitors, resolved the samples by Trisglycine SDSPAGE, transferred the samples to a polyvinylidene fluoride membrane and blotted them with the indicated anti bodies. Prkce translocation was performed as previously described 59 . For the fractionation of the lipid droplets, we grounded liver tissues in TrisEDTA buffer supplemented with proteasome inhibitors and ultracentrifuged the samples against 250 mM sucrose using a Beckman SW 40Ti roter at 35,000 rpm for 1.5 h at 4 °C. We separated the top lipid droplet fractions, delipidated them and analyzed them using western blot. We purchased antibodies to the following from commercial resources: Hdac3, Cidec and Fitm1 (Abcam), Plin2 (Progen), Ran (BD Biosciences), pSer473 Akt, total Akt and Hsp90 (Cell Signaling) and G0S2 (Santa Cruz). All antibodies were used at 1:1,000 to 1:5,000 dilution. For qRTPCR, we extracted total RNA using TRIzol (Invitrogen) and a High Pure RNA tissue kit (Roche). We performed qRTPCR with a High Capacity RT kit, a SYBR Green PCR Master Mix and the PRISM 7500 instrument (ABI) using the absolute quantification method with standard curves. We used 36B4 (Arbp) as the housekeeping control. The microarray analysis was performed as previously described 22 , and the data is available at Gene Expression Omnibus GSE25937.
Histology. For the H&E staining, we fixed tissues in 4% paraformaldehyde over night, dehydrated the samples, paraffin embedded them and prepared 5µm sections. For the Oil Red O staining, we prepared 5µm frozen sections from snapfrozen liver tissues and fixed them in 10% buffered formalin for 3 min. We then stained the sections in 0.5% Oil Red O in propylene glycerol and then in hematoxylin for staining the nuclei for 5 s. We performed immunohistochem istry and immunofluorescence staining on paraffin sections with antibodies to GFP (Abcam), F4/80 (Invitrogen), Plin2 and Plin3 (ref. 60) according to standard protocols. Antibodies were used at 1:500 dilutions.
Metabolite measurements. We measured serum triglyceride (Stanbio), ketone bodies (Stanbio), total FFA (Wako) and insulin (Crystal Chem) using com mercial kits. For measuring tissue triglyceride, we homogenized tissues in lysis buffer (140 mM NaCl, 50 mM Tris and 1% Triton X100, pH 8.0) and quantified the triglyceride concentration in the lysates using a LiquiColor trig lyceride assay kit (Stanbio) 13, 22 . For measuring glycogen, we homogenized tissues in 0.5 N potassium hydroxide, precipitated the glycogen using ethanol and digested it with 0.25 mg ml −1 amyloglycosidase (Sigma). We quantified the resultant glucose concentrations using a glucose HK assay (Sigma). DAG was analyzed by the Mouse Metabolic Phenotyping Center, Diabetes Research and Training Center Lipid Lab at Vanderbilt University. Lipids were extracted using the Folch method and separated by thin layer chromatography, followed by an analysis on an Agilent 7890A gas chromatograph with known standards. Hepatic ceramide was analyzed by the Mouse Metabolic Phenotyping Center Metabolomics Core at Yale. We extracted acylCoA with chloroform and meth anol (2:1, v/v), along with isotopelabeled internal standards, and generated an acylCoA profile by flow injection tandem mass spectrometry using the unique neutral loss of m/z = 507. We determined the acylCoA concentrations by the intensity of each acylCoA species to the nearest chainlength internal stand ards and normalized the values to the wet weight of the tissue. We measured plasma acylcarnitines by flowinjection tandem mass spectrometry with an analysis of the parent ion of the fragment with m/z = 85, along with isotope labeled internal standards.
Fatty acid oxidation, uptake and glucose production in hepatocytes.
We isolated primary hepatocytes, plated them in triplicates in complete DMEM medium and washed them with PBS after attachment. For the oxidation and uptake of fatty acids, we incubated cells in PBS supplemented with 62.5-250 µM 3 Hpalmitate conjugated on BSA and carnitine for 15-120 min. We delipidated the incubation solution and measured 3 H 2 O using a scintillation counter. We then washed the cells two times with PBS and harvested them. We extracted intracellular lipids using the Folch method and measured 3 H in a scintillation counter. For glucose production, we isolated hepatocytes from mice fasted over night and further starved the cells in Krebs buffer for 1 h after attachment. We then incubated the cells with Krebs buffer supplemented with different sub strates for 2 h. We quantified glucose production in the incubation solution using an HK assay kit (Sigma).
Hepatic triglyceride secretion. We fasted mice for 4 h and injected them intra peritoneally with 400 µl 7.5% Pluonic 407 (Poloxamer P407, Fisher) solution in PBS. We collected blood over a time course and quantified plasma triglycerides using a triglyceride assay kit (Stanbio).
De novo lipogenesis.
We injected deuterated water intraperitoneally (20 µl per g body weight) and euthanized the mice after 4 h. We extracted lipids from the liver and analyzed them using gas chromatography-mass spectrometry. We determined the percentage contribution of newly made fatty acid using the fol lowing equation: percentage of newly made fatty acid = (total 2 Hlabeled fatty acid/( 2 Hlabeled body water × n)) × 100, where n is the number of exchangeable hydrogens, assumed to equal 22 for palmitate and 23 for oleate. We determined the absolute amount of newly synthesized fatty acids by multiplying the percent age of newly made fatty acids by the concentration of the total fatty acids.
Hyperinsulinemic-euglycemic clamp. The clamp study was performed by the Mouse Phenotyping, Physiology and Metabolism Core at the University of Pennsylvania. Human insulin was infused at 2.5 mU per kg body weight per min, and blood glucose concentrations were maintained at between 120 and 140 mg dl −1 by infusing 20% glucose at various rates. 3 Hglucose was used to trace hepatic glucose production and glucose turnover.
Statistics.
A Student's twotailed t test was performed for all experiments to determine the significance of the differences between two groups. 
